TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36478528
Drug: Follitropin delta
Normalized name: follitropin delta
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Follitropin delta 24 μg
Study: 36478528
Drug: Follitropin delta
Normalized name: follitropin delta
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Follitropin delta (all doses)
Study: 33799044
Drug: CORT (20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CORT (20mg oral cortisol)
Study: 33242083
Drug: 3-week antibiotic
Normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-week antibiotic therapy
Study: 33242083
Drug: 6-week antibiotic
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6-week antibiotic therapy
Study: 32618207
Drug: Multimodal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal therapy (MT)
Study: 37682792
Drug: Zanubrutinib (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanubrutinib (160 mg twice daily)
Study: 33992421
Drug: Intramuscular progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular progesterone (50 mg daily)
Study: 33992421
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (200 mg vaginal micronized progesterone twice daily + 50 mg intramuscular progesterone every third day)
Study: 33992421
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone only (200 mg twice daily)
Study: 33992421
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone supplemented with intramuscular progesterone
Study: 34499874
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus ramucirumab (10 mg/kg on day 1 every 3 weeks)
Study: 34499874
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus placebo (intravenous placebo on day 1 every 3 weeks)
Study: 33357203
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (0.6 mL/kg/day orally for 10 days) + phototherapy
Study: 34554688
Drug: High-concentration capsaicin
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-concentration capsaicin (HCCP) 179 mg (8% w/w) cutaneous patch
Study: 34554688
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral pregabalin (150-600 mg)
Study: 33740568
Drug: IV ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV ibuprofen 400 mg
Study: 36890738
Drug: Indirect pulp
Normalized name: acai fruit pulp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect pulp treatment (IPT)
Study: 37916745
Drug: Antioxidant therapy
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant therapy
Study: 32749096
Drug: Lentinex® (1–2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lentinex® (1–2 mL/day, 1–2 mg beta-glucan)
Study: 34246609
Drug: Lung ultrasound
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung ultrasound (LUS)-guided treatment strategy
Study: 35580191
Drug: Rivaroxaban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (10 mg once daily for 3 weeks starting 7 ± 2 days after surgery)
Study: 34360032
Drug: Percussion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percussion therapy group (PTG)
Study: 33559437
Drug: Dragon-tiger fighting
Normalized name: Dragon
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dragon-tiger fighting needling therapy, applied at Sanyinjiao (SP 6), Zusanli (ST 36), Yinlingquan (SP 9), and Xuehai (SP 10), once daily for 2 courses of 2 weeks each.
Study: 33559437
Drug: Pregabalin capsules,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin capsules, 75 mg, twice a day for 2 courses of 2 weeks each.
Study: 33559437
Drug: Dragon-tiger fighting
Normalized name: Dragon
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dragon-tiger fighting needling therapy
Study: 33559437
Drug: Pregabalin capsules
Normalized name: Pregabalin Capsules
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin capsules
Study: 35023260
Drug: nanocurcumin (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: nanocurcumin (160 mg/day for 6 days)
Study: 32888085
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol (15 mg/kg/6 h for 3 days)
Study: 32888085
Drug: Intravenous ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous ibuprofen (10-5-5 mg/kg/day)
Study: 34600487
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment (Control)
Study: 32996330
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (120,000 IU monthly for 6 months)
Study: 616358275
Drug: Specialized immunonutrition
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialized immunonutrition (SIM) providing supplemental L-arginine, fish oil, vitamin A, and nucleotides
Study: 616358275
Drug: Calorie- and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calorie- and nitrogen-matched oral nutrition supplement (ONS)
Study: 32020360
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with bismuth (esomeprazole 20 mg twice a day, amoxicillin 1 g thrice daily, metronidazole 400 mg thrice daily, and bismuth 220 mg twice a day)
Study: 32020360
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy without bismuth (esomeprazole 20 mg twice a day, amoxicillin 1 g thrice daily, metronidazole 400 mg thrice daily)
Study: 33006567
Drug: eMBCT (online
Approvals — FDA: no, EMA: no, PMDA: no
Description: eMBCT (online mindfulness-based cognitive therapy)
Study: 34981547
Drug: SAMe enteric-coated
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAMe enteric-coated tablets in fasting condition
Study: 34981547
Drug: SAMe enteric-coated
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAMe enteric-coated tablets in postprandial condition
Study: 34981547
Drug: SAMe enteric-coated
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAMe enteric-coated tablets in both conditions
Study: 39231871
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg caffeine
Study: 34125632
Drug: EoS of
Normalized name: EO-3021
DrugBank: EO-3021 (DB18358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EoS of either tablet
Study: 34344675
Drug: OMPRIS intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OMPRIS intervention (4-week psychological intervention based on motivational interviewing, addiction therapy, behavioral therapy techniques, and social counseling)
Study: 32721437
Drug: Budesonide Orodispersible
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide Orodispersible Tablet (BOT) 0.5 mg twice daily
Study: 32721437
Drug: Budesonide Orodispersible
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide Orodispersible Tablet (BOT) 1.0 mg twice daily
Study: 35388956
Drug: G‐CEM LinkForce
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CEM LinkForce (GCL) adhesive resin cement with G‐Premio Bond in selective etch mode
Study: 35943958
Drug: Group-based eight-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based eight-week cognitive-behavioral therapy (CBT) treatment program
Study: 35083739
Drug: Tramadol chewable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol chewable tablet (1 mg/kg)
Study: 35083739
Drug: Tramadol chewable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol chewable tablet
Study: 35083739
Drug: Tramadol hydrochloride
Normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol hydrochloride oral liquid (1 mg/kg)
Study: 34963451
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy (NPWT) for 1 week (Group B)
Study: 34963451
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy (NPWT) for 2 weeks (Group C)
Study: 38573517
Drug: Romosozumab 210
Normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romosozumab 210 mg monthly
Study: 35866376
Drug: Teriparatide 20
Normalized name: TERIPARATIDE 200UNT/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide 20 μg daily
Study: 36204223
Drug: Esketamine 20
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine 20 mg (diluted with 0.9% normal saline, 1 ml)
Study: 36204223
Drug: Esketamine 12
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine 12 mg (diluted with 0.9% normal saline, 1 ml)
Study: 36204223
Drug: Esketamine 4
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine 4 mg (diluted with 0.9% normal saline, 1 ml)
Study: 33835103
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard pain management medication)
Study: 37335992
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of aspirin daily
Study: 35666489
Drug: Strain-counterstrain technique
Normalized name: Haemagglutinin-strain B
DrugBank: Haemagglutinin-strain B (DB15482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strain-counterstrain technique (SCS) combined with standard therapy (active range of motion, stretching exercises, and postural correction exercises)
Study: 35666489
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy only (active range of motion, stretching exercises, and postural correction exercises)
Study: 34919626
Drug: Zygomatic implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zygomatic implant combined with 'three-dimensional ring'-supported prosthetics (group 3)
Study: 34919626
Drug: Regular implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular implant with obturator removal (group 2)
Study: 33574139
Drug: IgM titre‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgM titre‐based treatment with a personalised daily dose based on IgM serum titre aimed at achieving serum titres above 100 mg/dL
Study: 33574139
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment group receiving IgM enriched preparation daily for three consecutive days at the standard dose of 250 mg/kg
Study: 33009187
Drug: Prophylactic fibrinogen
Normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic fibrinogen concentrate (Haemocomplettan P) at a mean dose of 79 mg kg‐1 body weight
Study: 33493256
Drug: MEDI6012 120
Normalized name: MEDI6012
DrugBank: MEDI6012 (DB14833)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI6012 120 mg
Study: 33493256
Drug: MEDI6012 300
Normalized name: MEDI6012
DrugBank: MEDI6012 (DB14833)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI6012 300 mg
Study: 33493256
Drug: IV-push 300
Normalized name: evolocumab
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV-push 300 mg
Study: 32331011
Drug: Active rTMS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active rTMS treatment (3500 pulses at 10 Hz to left dlPFC and 1500 pulses at 1 Hz to right dlPFC)
Study: 32501814
Drug: Ethanol-containing gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol-containing gel with 5% urea applied twice daily for 17 days
Study: 616115932
Drug: Geriatric assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Geriatric assessment (GA) administered via a mostly self‐administered, tablet‐based system within 72 hours of hospitalization.
Study: 616115932
Drug: Provision of
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provision of GA results to treating clinicians within 24 hours of GA administration.
Study: 36161640
Drug: USG-guided FICB
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: USG-guided FICB with 15 mL bupivacaine + 10 mL 2% lidocaine
Study: 36161640
Drug: Landmark approach
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Landmark approach FICB with 15 mL bupivacaine + 10 mL 2% lidocaine
Study: 35737144
Drug: Chaihu plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chaihu plus Longgu Muli decoction with five-element music therapy
Study: 35737144
Drug: Escitalopram tablets
Normalized name: Escitalopram Tablets
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram tablets (Control)
Study: 35698101
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg oxycodone
Study: 33441058
Drug: Nebulized amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized amphotericin B twice daily
Study: 33441058
Drug: Nebulized amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized amphotericin B 3 times daily
Study: 34402029
Drug: GBCS model
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBCS model (10-year sex-specific CVD risk prediction model including age, systolic blood pressure, use of antihypertensive medication, smoking, and diabetes)
Study: 35383116
Drug: OrienX010 (8×10^7
Approvals — FDA: no, EMA: no, PMDA: no
Description: OrienX010 (8×10^7 pfu/mL) intratumoral injections, up to 5 mL every 2 weeks (cohort 08)
Study: 35383116
Drug: OrienX010 (8×10^7
Approvals — FDA: no, EMA: no, PMDA: no
Description: OrienX010 (8×10^7 pfu/mL) intratumoral injections, up to 10 mL every 2 weeks (cohort 09)
Study: 36280151
Drug: Accelerated hypofractionated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated hypofractionated radiation therapy (1.8 Gy daily to PTV + 0.6 Gy boost to GTV, total 45 Gy to PTV and 60 Gy to GTV in 25 fractions over 5 weeks)
Study: 36280151
Drug: Conventional fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fractionated radiation therapy (2 Gy daily to PTV, total 44 Gy to PTV and 60 Gy to GTV in 30 fractions over 6 weeks)
Study: 32468646
Drug: Nilotinib 150
Normalized name: nilotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilotinib 150 mg orally once daily for 26 weeks
Study: 32468646
Drug: Nilotinib 300
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib 300 mg orally once daily for another 26 weeks
Study: 36014916
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of DHA from algal oil per day
Study: 36014916
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule per day
Study: 35442755
Drug: ET with
Normalized name: Venoset with Clamp
Approvals — FDA: no, EMA: no, PMDA: no
Description: ET with ibandronate 50 mg once daily for 3 years
Study: 33986453
Drug: Ag NPs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ag NPs at 15 mL/L
Study: 33986453
Drug: Ag NPs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ag NPs at 12.5 mL/L
Study: 33986453
Drug: Zn NPs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zn NPs at 7.5 mL/L
Study: 33986453
Drug: Ag NPs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ag NPs treated leaves extract at 3000 µg/mL
Study: 35564623
Drug: Heart Rate
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart Rate Variability Biofeedback (HRVBFB) plus Treatment as Usual (TAU)
Study: 32163509
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (TAU) only
Study: 34357722
Drug: Immunomodulatory drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomodulatory drug based on muramilpeptides
Study: 34357722
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with no muramilpeptides‐based agent
Study: 32242541
Drug: Nutrition intervention
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition intervention (9-month duration) including weekly classroom education, after-school cooking classes, and online materials
Study: 35103343
Drug: Itraconazole pulse
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole pulse therapy
Study: 35103343
Drug: Combined itraconazole/acitretin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined itraconazole/acitretin therapy
Study: 32324898
Drug: Number of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of drugs used in the hospital
Study: 32423467
Drug: Two drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two drug regimens
Study: 36318852
Drug: Prostatilen (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostatilen (reference drug)
Study: 34217337
Drug: Compound Sodium
Normalized name: SODIUM CHLORIDE 6 g in 1 L / SODIUM LACTATE 3.22 g in 1 L / POTASSIUM CHLORIDE 400 mg in 1 L / CALCIUM CHLORIDE 270 mg in 1 L INTRAVENOUS INJECTION, SOLUTION [COMPOUND SODIUM LACTATE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Sodium Lactate
Study: 34229475
Drug: Brief manual
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief manual standardized stress acupuncture (MSSA) combined with abbreviated Cognitive Behavioral Therapy (ACBT)
Study: 32722659
Drug: MR stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR stimulation (fludrocortisone 0.4 mg + placebo)
Study: 32722659
Drug: NMDA-R stimulation
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: NMDA-R stimulation (placebo + D-cycloserine 250 mg)
Study: 32722659
Drug: MR and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR and NMDA-R stimulation (both drugs)
Study: 33030042
Drug: 8-week tinnitus-specific
Normalized name: PACIFIC OYSTER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-week tinnitus-specific cognitive behavioral therapy (CBT) and personalized sound therapy via smartphone application
Study: 35798455
Drug: Mavacamten, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavacamten, 5 mg daily, titrated up to 15 mg based on LVOT gradient and LV ejection fraction
Study: 34312088
Drug: Long testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long testosterone (12.5 mg/day testosterone gel for 56 days)
Study: 34312088
Drug: Short testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short testosterone (12.5 mg/day testosterone gel for 10 days)
Study: 35341320
Drug: Mesenchymal stem
Normalized name: Human mesenchymal stem cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesenchymal stem cells (MSCs) intravenous injection
Study: 36407493
Drug: Nanoemulsion oral
Normalized name: ANA-conjugated dactinomycin nanoemulsion
DrugBank: Dactinomycin (DB00970)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nanoemulsion oral solution (60,000 IU cholecalciferol)
Study: 36407493
Drug: Soft gelatin
Normalized name: Norvir Soft Gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft gelatin capsules (60,000 IU cholecalciferol)
Study: 33580564
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment (T) + Exercise (Ex)
Study: 33739155
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment (T)
Study: 34733561
Drug: Physiotherapy (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy (12 sessions, twice a week for 6 weeks)
Study: 34733561
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (80 mg of methylprednisolone and 1 ml of lidocaine 2% in two stages, 21 days apart)
Study: 34733561
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of physiotherapy and corticosteroid injection (80 mg of methylprednisolone and 1 ml of lidocaine 2%, followed by 6 sessions of physiotherapy twice a week for 3 weeks)
Study: 35194862
Drug: E-cigarette starter
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E-cigarette starter pack with weekly allocations of nicotine containing e-liquid for 4 weeks (flavours: menthol, fruit, tobacco; strengths: 12 mg/mL and 18 mg/mL)
Study: 34113094
Drug: Inhaled nemiralisib
Normalized name: Nemiralisib
DrugBank: Nemiralisib (DB16253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nemiralisib (1mg) in stable COPD
Study: 34113094
Drug: Inhaled nemiralisib
Normalized name: Nemiralisib
DrugBank: Nemiralisib (DB16253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nemiralisib (1mg) in AECOPD
Study: 33319866
Drug: Ramelteon (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon (0.1 mg kg-1 dissolved in 5 mL of lactose-containing syrup)
Study: 33319866
Drug: Placebo (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (same amount of syrup alone)